EpiCast Report: Postherpetic Neuralgia - Epidemiology Forecast to 2022

Publisher Name :
Date: 22-Oct-2013
No. of pages: 45

Postherpetic Neuralgia (PHN) is one of the most common complications of herpes zoster infection in elderly persons ages 60 years and older, worldwide. The main symptom of PHN is severe pain and allodynia (pain that results from a non-injurious stimulus to the skin). PHN is associated with a significant loss of activity levels and a reduced quality of life, particularly in the elderly. The strongest established risk factor for PHN is advancing age. Other possible risk factors for PHN include severity of acute herpes zoster pain, extent of rash, and duration of prodromal pain.

The number of incident cases of PHN in the 7MM will increase by 20.22% over the next decade, from 241,808 cases in 2012, to 290,694 cases in 2022. Ageand sex-specific incidence data for PHN and herpes zoster, as well as data for the proportion of herpes zoster patients developing PHN in the 7MM, were obtained or calculated from nationally-representative studies in each country to forecast the incident cases of PHN. To maintain a uniform methodology across the markets, GlobalData epidemiologists only used studies that defined PHN as pain persistent for three or more months.

Currently, there is no absolute preventative therapy for PHN. However, a vaccine is available to help prevent a herpes zoster infection; in turn, this vaccine helps reduce the incidence of PHN to an extent because PHN is the sequela of herpes zoster. The considerable increase in the aging population worldwide, coupled with the high risk for developing PHN in elderly herpes zoster patients are expected to impose a considerable burden on healthcare in the 7MM in future years.

Scope


  • The Postherpetic Neuralgia EpiCast Report provides an overview of the risk factors and global trends of postherpetic neuralgia in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast (2012–2022) of the incident cases of postherpetic neuralgia segmented by age (in five-year increments beginning at age 50 and ending at age =85 years) and sex in the 7MM.

  • The postherpetic neuralgia epidemiology report is written and developed by Mastersand PhD-level epidemiologists.

  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.


Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global postherpetic neuralgia market.

  • Quantify patient populations in the global postherpetic neuralgia market to improve product design, pricing, and launch plans.

  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for postherpetic neuralgia therapeutics in each of the markets covered.

EpiCast Report: Postherpetic Neuralgia - Epidemiology Forecast to 2022

Table of Contents

1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 6

2 Introduction 7
2.1 Catalyst 7

3 Epidemiology 8
3.1 Disease Overview 8
3.2 Risk Factors and Comorbidities 9
3.2.1 Elderly herpes zoster patients are almost 20 times more likely to develop PHN 9
3.2.2 Herpes zoster vaccine reduces the morbidity of herpes zoster and PHN 11
3.3 Global Trends 11
3.3.1 US 12
3.3.2 France 13
3.3.3 Germany 14
3.3.4 Italy 14
3.3.5 Spain 15
3.3.6 UK 16
3.3.7 Japan 17
3.4 Forecast Metodology 17
3.4.1 Sources Used 19
3.4.2 Forecast Assumptions and Methods 22
3.4.3 Sources Not Used 26
3.5 Epidemiological Forecast of Postherpetic Neuralgia (2012–2022) 27
3.5.1 Incident Cases of PHN 27
3.5.2 Age-Specific Incident Cases of PHN 28
3.5.3 Sex-Specific Incident Cases of PHN 30
3.5.4 Age-Standardized Incidence of PHN 32
3.6 Discussion 33
3.6.1 Epidemiological Forecast Insight 33
3.6.2 Limitations of the Analysis 34
3.6.3 Strengths of the Analysis 35

4 Appendix 37
4.1 Bibliography 37
4.2 About the Authors 40
4.2.1 Epidemiologists 40
4.2.2 Reviewers 40
4.2.3 Franka des Vignes, PhD, Global Director of Epidemiology and Health Policy 42
4.2.4 Bonnie Bain, PhD, Global Head of Healthcare 42
4.3 About GlobalData 43
4.4 About EpiCast 43
4.5 Disclaimer 44

List of Tables

Table 1: 7MM, Sources of PHN Incidence Data 18
Table 2: 7MM, Incident Cases of PHN, Ages ?50 Years, Men and Women, N, 2012–2022 27
Table 3: 7MM, Incident Cases of PHN, by Age, Men and Women, N (Row %), 2012 29
Table 4: 7MM, Incident Cases of PHN, by Sex, Ages ?50 Years, N (Row %), 2012 31

List of Figures

Figure 1: 7MM, Incident Cases of PHN, Ages ?50 Years, Men and Women, N, 2012–2022 28
Figure 2: 7MM, Incident Cases of PHN, by Age, Men and Women, N, 2012 30
Figure 3: 7MM, Incident Cases of PHN, by Sex, Ages ?50 Years, N, 2012 31
Figure 4: 7MM, Age-Standardized Incidence of PHN (per 1,000 Population), Ages ?50 Years, Men and Women, 2012 33

  • Packaging Sector Driven By Innovation
    The financial development in numerous emerging nations has significantly influenced the progress of quite a lot of sectors, the packaging industry being one of them. The swell in transport undertakings outfitting to a substantial number of industries such as manufacturing, consumer goods, food and beverages, and others rest essentially on sturdy and resilient packaging solutions [...]
  • Global Eyewear Market To Gain From Increased Demand For Disposable Contact Lenses
    The global eyewear market was worth US$ 102.66 billion in 2015 and is predictable to reach US$ 184.03 billion by 2024. The rising population and upsurge in the number of optical disorders are likely to propel the industry in the near future. Moreover, the increasing cognizance amongst people as regards to the prominence of eye [...]
  • Global mHealth Market To Become A Multi-Billion Dollar Industry By 2020
    The mHealth market is in its embryonic stage and is projected to produce substantial profits with amassed awareness level and encouraging regulatory guidelines particular to the quality and practicality of mobile-based medical devices. The global mHealth market is projected to touch US$ 49.12 billion by 2020 rising at a CAGR of 47.6% from 2013 to 2020. Monitoring services [...]
  • Efficacy of Stand-alone Power Sources Drive The Global Distributed Energy Generation Market
    The global market for distributed energy generation is expected to magnify at a momentous CAGR of 11.4% between 2016 and 2020. The small-scale generation of electricity, oscillating from a few kilowatts to multitudes of megawatts, is denoted as distributed energy generation. In this process, power is usually produced using renewable resources or by generators during consumption. [...]
  • Global Organic Food Market Makes A Mark in Developed Economies
    Buyers throughout the world are becoming more and more health cognizant, which has occasioned in an alteration in their palates and inclinations. The global organic food market was worth US$88.1 billion in 2015 is anticipated to record a CAGR of over 16% between 2015 and 2020. Amongst the various different food products available, the fruits [...]
  • Moderate Pain-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
    Published: 01-Jan-2017        Price: US 2000 Onwards        Pages: 100
    DelveInsight's Report, "Moderate Pain-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Moderate Pain Report is to understand the market and pipeline status of the drugs around the Moderate Pain to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designi......
  • Musculoskeletal Pain-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
    Published: 01-Jan-2017        Price: US 2000 Onwards        Pages: 100
    DelveInsight's Report, "Musculoskeletal Pain-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Musculoskeletal Pain Report is to understand the market and pipeline status of the drugs around the Musculoskeletal Pain to explore the generic development opportunities, licensing opportunities and to gain competitive......
  • Post-Operative Pain-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
    Published: 01-Jan-2017        Price: US 2000 Onwards        Pages: 100
    DelveInsight's Report, "Post-Operative Pain-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Post-Operative Pain Report is to understand the market and pipeline status of the drugs around the Post-Operative Pain to explore the generic development opportunities, licensing opportunities and to gain competitive ad......
  • Mild Pain-Pipeline Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Mild Pain-Pipeline Insights, 2017", report provides in depth insights on the pipeline drugs and their development activities around the Mild Pain. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings,......
  • Moderate Pain-Pipeline Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Moderate Pain-Pipeline Insights, 2017", report provides in depth insights on the pipeline drugs and their development activities around the Moderate Pain. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, f......
  • Acute Pain-API Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have......
  • Musculoskeletal Pain-Pipeline Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Musculoskeletal Pain-Pipeline Insights, 2017", report provides in depth insights on the pipeline drugs and their development activities around the Musculoskeletal Pain. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, a......
  • Myalgia-Pipeline Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Myalgia-Pipeline Insights, 2017", report provides in depth insights on the pipeline drugs and their development activities around the Myalgia. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, pat......
  • Non Malignant pain-Pipeline Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Non Malignant pain-Pipeline Insights, 2017", report provides in depth insights on the pipeline drugs and their development activities around the Non Malignant pain. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acqui......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs